A5037644466- Atrial Fibrillation Management and Outcomes
- Venous Thromboembolism Diagnosis and Management
- Cardiac Arrhythmias and Treatments
- Blood Coagulation and Thrombosis Mechanisms
- Antiplatelet Therapy and Cardiovascular Diseases
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Acute Myocardial Infarction Research
- Cardiac, Anesthesia and Surgical Outcomes
- Intracerebral and Subarachnoid Hemorrhage Research
- Heparin-Induced Thrombocytopenia and Thrombosis
- Cardiovascular Issues in Pregnancy
- Health Systems, Economic Evaluations, Quality of Life
- Cancer Treatment and Pharmacology
- Urticaria and Related Conditions
- Vitamin K Research Studies
- Acute Ischemic Stroke Management
- Pharmacovigilance and Adverse Drug Reactions
- Gastroesophageal reflux and treatments
- Systemic Sclerosis and Related Diseases
- Cardiac electrophysiology and arrhythmias
- Poisoning and overdose treatments
- Cardiovascular Syncope and Autonomic Disorders
- Electrolyte and hormonal disorders
- Potassium and Related Disorders
- Cerebrovascular and Carotid Artery Diseases
University Hospital Carl Gustav Carus
2016-2025
Technische Universität Dresden
2014-2025
Center for Vascular Biology Research
2014
Summary The effectiveness and safety of rivaroxaban for stroke prevention in atrial fibrillation (SPAF) demonstrated ROCKET AF needs to be confirmed daily care. To evaluate therapy SPAF patients care, we used data from an ongoing, prospective, non-interventional registry more than 2700 on novel oral anticoagulants Between October 1, 2011 February 28, 2013, a total 1204 receiving were enrolled. During mean follow-up 796.2 ± 207.3 days, the combined endpoint stroke/transient ischaemic...
Worldwide, rivaroxaban is increasingly used for stroke prevention in atrial fibrillation (SPAF) but little known about the rates of or reasons discontinuations daily care. Using data from a prospective, non-interventional oral anticoagulation (NOAC) registry, we analysed treatment persistence. Persistence with SPAF was assessed an ongoing, registry >2600 NOAC patients care using Kaplan–Meier time-to-first-event analysis. Reasons and management discontinuation were assessed. Potential...
The effectiveness and safety of dabigatran for stroke prevention in atrial fibrillation (SPAF) demonstrated RE-LY needs to be confirmed daily care. To evaluate treatment persistence, therapy SPAF patients care, we used data from an ongoing, prospective, non-interventional registry more than 2,500 on novel oral anticoagulants Between October 1, 2011 February 28, 2013, a total 341 receiving were enrolled. combined endpoint stroke/transient ischaemic attack/systemic embolism occurred at rate...
Summary Today, direct oral anticoagulants (DOAC) are widely used alternatives to Vitamin-K antagonists (VKA). Women of reproductive age may become pregnant during anticoagulation and, while VKA carry an embryotoxic potential, the risk DOAC embryopathy is unknown. As a result, some patients elect terminate pregnancy for fear embryotoxicity. To assess embryopathy, we reviewed cases exposure in collected from physicians, literature and pharmacovigilance systems drug authorities manufacturers. A...
Vitamin-K antagonists (VKA) and non-vitamin-K dependent oral anticoagulants (NOAC) have been approved for anticoagulation in venous thromboembolism (VTE) atrial fibrillation patients previously treated with VKA are switched to NOAC therapy. Safety data this switching urgently needed.Using from a large regional prospective registry of daily care patients, we evaluated the safety dabigatran or rivaroxaban. Switching procedures cardiovascular bleeding events occurring within 30 days after were...
Prospective trials have shown that rivaroxaban thromboprophylaxis is superior over low-molecular-weight heparin (LMWH) in patients undergoing hip and knee replacement surgery. However, treated under trial conditions are different from unselected routine patients, which may affect efficacy safety of thromboprophylaxis. The objective was to evaluate the or LMWH surgery daily care. In a monocentric, retrospective cohort study 5,061 consecutive comparison (hospital standard 2006-2007) (since...
Atrial fibrillation (AF) patients treated with well-controlled vitamin K antagonists (VKAs) may benefit less from non-vitamin antagonist oral anticoagulants (NOACs) because they are supposed to be at low risk of thromboembolic and bleeding complications. However, little is known about the selection, management, outcome such "stable" VKA in current practice. We assessed characteristics, persistence 12 months' AF selected for continuation. On March 1, 2013, Dresden NOAC registry opened...
Background: In the ROCKET-AF trial, novel oral anticoagulant (NOAC) rivaroxaban has been found to be at least as effective and safe warfarin for stroke prevention in atrial fibrillation (SPAF). As a consequence, become approved many countries. However, patients RCT's present selected population which is treated under strict protocol followed short period of time. Consequently, efficacy safety need confirmed unselected daily care. Objectives: To evaluate efficacy, management issues...
IntroductionData on long-term effectiveness and safety of rivaroxaban for stroke prevention in atrial fibrillation (SPAF) are scarce not available from randomized clinical trials.MethodsWe used data the prospective, non-interventional DRESDEN NOAC REGISTRY to evaluate rates stroke/transient ischaemic attack (TIA)/systemic embolism (SE) ISTH major bleeding, general changes event patterns over time.ResultsBetween 1st October 2011 31st December 2022, 1204 SPAF patients receiving were followed...